CLINICAL_TRIALS ClinicalTrials.gov record update

A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01111903
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:15.741780+00:00
Published At: 2016-03-17T00:00:00+00:00
Record Updated At: 2016-03-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ovarian Cancer Recurrent"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-03-17"
protocolSection.identificationModule.nctId: "NCT01111903"
protocolSection.identificationModule.officialTitle: "A Two Stage Trial of l\u00e9nalidomide (Revlimid\u00ae) : a Phase II Study of l\u00e9nalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of l\u00e9nalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin."
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.